BIOTECH MARKET RESEARCH $RLAY | Ep. 948
Relay Therapeutics
Relay Therapeutics ($RLAY) has become a catalyst-driven trade into its ASCO June 2026 update on zovegalisib (RLY-2608) in 2L HR+/HER2- PIK3CA-mut metastatic breast cancer, with investors framing the presentation as a referendum on whether the 400 mg BID fed pivotal dose can reproduce the earlier 10.3-month mPFS signal seen at 600 mg fasted. The stock only re-rates if ASCO demonstrates durable PFS in the ≥9–10 month range with ORR holding in the mid-to-high 30s, reinforcing the mutant-selective PI3Kα differentiation thesis versus capivasertib and legacy PI3K inhibitors. Investors will overweight absolute median PFS, separation from the historical 5–7 month CDK4/6-experienced benchmark, consistency across kinase and non-kinase PIK3CA subsets, and whether safety remains clearly cleaner on hyperglycemia and discontinuations at the fed dose used in Phase 3. If the ASCO dataset shows efficacy compression toward 7–8 months, right-tail erosion, or emerging metabolic toxicity that converges toward non-selective pathway inhibitors, the narrative shifts to “Phase 2 inflation risk,” pressuring confidence in ReDiscover-2 and pushing RLAY back toward a binary, Phase 3-dependent story rather than a de-risked best-in-class setup. Options are pricing +/- 135% volatility.
Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.
We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).
Be sure to SUBSCRIBE to not miss.
HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS
While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.
This is not financial advice so you will have to make your own call on how to best play these events. Our aim is simply to flag catalysts with high projected volatility.
🚨 ALERT: ASCO data readout June 2026
📅 TIMING: June 2026
📈 IMPLIED MOVE: ~±135%
BACKGROUND:
